🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Management repeatedly uses 'strong', 'pleased', 'solid', and provides granular year-over-year growth percentages (e.g., 8.7% total revenue ex-Nova, 3.2% workers' comp visits ex-Nova, 4.4% revenue per visit). They proactively isolate M&A impacts and quantify integration milestones (70% synergies captured, 50% of separation hires completed).

Q3 2025

Confident Specific

Management uses positive language like 'strong quarter', 'solid year-over-year volume and rate growth', 'outperform the organic growth algorithm', and provides specific figures such as 17% revenue growth and 4.2% revenue per visit increase.

Q4 2025

Confident Specific

Management repeatedly uses specific figures and comparisons to prior periods, highlights exceeding guidance ('exceeding the high end of the range of our previously issued full year 2025 guidance'), and cites validation studies with concrete percentages (25% lower claims cost, 65 fewer days). Language is direct and forward-looking without hedging.

Q1 2026 latest

Confident Specific

Management repeatedly uses 'strong', 'pleased', 'significant', and provides specific figures like '13.7% revenue growth', '17.6% Adjusted EBITDA increase', and 'raised guidance' to convey conviction in results and outlook.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. Core workers' compensation volumes grew 9.6% (6.2% ex-Nova) and revenue per visit is on track for 3%+ for the year. Onsite health is accelerating with 20.9% organic growth and now approaching $150M run rate. Integration of Nova and Pivot is ahead of plan, providing confidence in M&A strategy and margin expansion. Free cash flow guidance was raised, and net leverage expected below 3x by year-end. Watch for: pace of de novo openings, New York rate decision, and whether employer services reaccelerates as economic hiring picks up.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Concentra Q1 2026 revenue $569.6M, adj. EBITDA $120.7M, raises full-year guidance.

Revenue & Profitability

Total revenue was $569.6 million in Q1 2026, up 13.7% from $500.8 million in Q1 2025. Adjusted EBITDA was $120.7 million, a 17.6% increase from $102.7 million. Adjusted net income attributable to the company was $51.5 million, or $0.40 per diluted share, compared to $42.2 million and $0.33 in the prior year. Operating cash flow was $21 million, and free cash flow totaled $9.9 million.

Outlook

Management views the current macroeconomic environment as a 'low hire, low fire' scenario, with employer services visits muted but workers' compensation benefiting from total employment growth, especially in blue-collar sectors. Onshoring of manufacturing and construction activity (including AI build-out) are seen as tailwinds. The company expects continued improvement in workers' compensation rate growth, including the California rate increase effective March 1, 2026.

Growth Drivers

Growth is driven by workers' compensation volume (up 9.6% visits per day), California rate increases, de novo center openings (8-10 planned in 2026 in states including Arizona, Idaho, Missouri, Illinois, Virginia, South Carolina, and Florida), and small bolt-on M&A. The Onsite Health Clinics segment grew 20.9% organically (excluding Pivot acquisition) and is a key growth lever with a $15-$20 billion serviceable addressable market.

Balance Sheet & CapEx

CapEx guidance for 2026 remains unchanged at $70-$80 million. In Q1 2026, investing activities used $14.8 million, driven by acquisitions of three centers in California, de novo centers, relocations, renovations, maintenance, and IT investments. The company is investing in IT infrastructure as part of its separation from Select, with more than 95% of new FTEs hired and functional separation expected by summer 2026.

Margins

Adjusted EBITDA margin improved from 20.5% in Q1 2025 to 21.2% in Q1 2026, a 69 basis point increase. Cost of services as a percentage of revenue improved to 70.1% from 71.3%. The company continues to realize staffing efficiencies in centers. G&A expenses (excluding add-backs) were 8.8% of revenue, up from 8.2% due to planned additions from the Select separation. For 2026, adjusted EBITDA guidance is $460-$480 million.

Key Risks

Risks include macroeconomic weakness in employer services due to low hiring, weather events (which can be both positive and negative), and the completion of the separation from Select (functional separation by summer 2026). The company also faces potential uncertainty from New York rate adjustments and visit mix shifts that can affect revenue per visit growth.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-08-07

Q2 2026 saw double-digit revenue growth, margin expansion, and strong free cash flow, prompting raised full-year guidance for revenue, EBITDA, and free cash flow. Leadership transition to a new CEO is underway, and operational execution remains strong amid favorable market trends.

Q1 2026 Q1 2026 2026-05-08

Q1 2026 saw double-digit revenue and EBITDA growth, driven by strong workers' compensation volumes, successful acquisition integrations, and improved margins. Guidance for 2026 was raised across revenue, EBITDA, and Free Cash Flow, with continued focus on expansion and operational efficiency.

Q4 2025 Q4 2025 2026-02-27

Revenue and Adjusted EBITDA exceeded guidance in 2025, driven by strong organic growth, successful acquisitions, and cost efficiencies. 2026 guidance projects continued growth, margin stability, and robust capital deployment, with a focus on de novos and small M&A.

Q3 2025 Q3 2025 2025-11-07

Q3 2025 saw 17% revenue growth and strong adjusted EBITDA, driven by organic and acquisition-fueled expansion. Guidance for 2025 was raised, with continued focus on deleveraging, technology investment, and disciplined M&A. No major headwinds are anticipated for 2026.

Q2 2025 Q2 2025 2025-08-08

Q2 2025 saw strong revenue and visit growth, successful integration of major acquisitions, and raised full-year guidance. Margins were slightly lower due to one-time costs, but cash flow and deleveraging remain on track. No major reimbursement or labor risks identified.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.